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Abstract In this open-label study, women aged 36–40 years undergoing ovarian stimulation were randomized to recombinant human
FSH (rhFSH) plus recombinant human luteinizing hormone (rhLH) from stimulation day 1 (group A; n = 103), or rhFSH alone (days
1–5) followed by rhFSH plus rhLH from day 6 (group B; n = 99). The primary objective was equivalence in number of oocytes
retrieved per patient. The mean (±SD) number of oocytes retrieved was 9.7 (±6.9) in group A and 10.9 (±6.5) in group B; the esti-
mated difference between groups (−1.28 oocytes [95% conﬁdence interval: −3.15 to 0.59]) did not reach the predeﬁned limit of equiva-
lence (±3 oocytes). The study’s primary objective was therefore not met. In both groups, a mean (±SD) of 1.9 (±0.6) embryos were
transferred per patient. Implantation rates were 24.7% in group A and 13.3% in group B. Clinical pregnancy rates per started cycle
and per embryo transfer were 31.6% and 34.4% in Group A, 17.2% and 18.9% in Group B. Ovarian hyperstimulation syndrome was
reported in four (group A) and ﬁve (group B) patients. The potential beneﬁt of initiating LH supplementation earlier during ovarian
stimulation in older women is of interest, warranting further exploration.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Women nowadays are generally having children at an older
age; this, combined with a natural reduction in fecundity as-
sociated with increasing age, has contributed to a rise in the
occurrence of female infertility worldwide (Alviggi et al., 2009;
Sharma et al., 2013; te Velde and Pearson, 2002; Ziebe and
Devroey, 2008). In turn, this has resulted in an increase in the
number of older (>35 years of age) women seeking infertil-
ity treatment through assisted reproduction techniques (Alviggi
et al., 2009; Sharma et al., 2013). Maternal age, however,
can affect the outcomes of assisted reproduction tech-
niques, with success rates generally declining as age in-
creases (Alviggi et al., 2009; Buhler et al., 2011; Centers for
Disease Control and Prevention, 2011; Human Fertilisation and
Embryology Authority, 2008; Kupka et al., 2010).
In 2007, the 2:1 formulation of recombinant human FSH
(rhFSH; follitropin alfa) and recombinant human luteinizing
hormone (rhLH; lutropin alfa) was launched in the European
Union, and is indicated for the stimulation of follicular de-
velopment in women with severe LH and FSH deﬁciency (en-
dogenous serumLH level less than1.2 international units [IU]/L;
Pergoveris, Merck Serono SA, Geneva, Switzerland) (Merck
Serono, 2014), also knownashypogonadotrophichypogonadism.
The role of LH in assisted reproduction protocols has been
debated for over 20 years. Measurement of LH levels during
ovarian stimulation are not predictive of outcome in
gonadotrophin-releasing hormone agonist protocols (Balasch
et al., 2001; Cabrera et al., 2005; Esposito et al., 2001;
Humaidan et al., 2002; Nakagawa et al., 2008; Westergaard
et al., 2000) or antagonist cycles (Griesinger et al., 2011). Ac-
cumulating evidence, however, suggests that the addition of
rhLH to rhFSH may be beneﬁcial for women aged ≥35 years
undergoing ovarian stimulation for assisted reproduction tech-
niques (Bosch et al., 2011; Hill et al., 2012; Marrs et al., 2004;
Matorras et al., 2009). A typical time point to start LH supple-
mentation is around day 6 of FSH stimulation (Marrs et al.,
2004; Matorras et al., 2009), and this is based upon the premise
that LH plays an essential role in the ﬁnal stages of follicu-
lar maturation (Hillier, 2001). Although these studies gener-
ally report comparable numbers of oocytes being retrieved
with or without LH supplementation, a recent meta-analysis
of pooled data from seven trials found signiﬁcantly higher rates
of implantation (odds ratio [OR], 1.36, 95% conﬁdence inter-
val [CI]: 1.05 to 1.78) and clinical pregnancy (OR, 1.37, 95%
CI: 1.03 to 1.83) in women aged ≥35 years treated with rhFSH
plus rhLH compared with those receiving rhFSH alone (Hill
et al., 2012). Some studies in older women (Fabregues et al.,
2006; Konig et al., 2013) and a subgroup analysis in women
aged over 35 years (Nyboe Andersen et al., 2008) have not
demonstrated a beneﬁt of LH supplementation. Currently, no
consensus has been reached on the use or optimal time to
initiate LH supplementation during ovarian stimulation in
older women undergoing assisted reproduction techniques.
The open-label, randomized PERSIST (PERgoveriS In Strati-
ﬁed Treatment for ART) study reported here was designed to
generate data on the ovarian stimulation proﬁle obtained when
the 2:1 formulation of rhFSH plus rhLH was started either
on stimulation day 1 or stimulation day 6 in patients aged
36–40 years who were undergoing ovarian stimulation for as-
sisted reproduction techniques, with a secondary objective
of further investigating the efﬁcacy and safety proﬁle of rhFSH
plus rhLH (2:1) in this population of women.
Materials and methods
Study design
This was a prospective, phase IIIb, randomized, open-label,
multi-national study (Clinicaltrials.gov identiﬁer:NCT01297465)
conducted inwomen aged between 36 and 40 years undergoing
ovarian stimulation for ART using rhFSH plus rhLH. An over-
view of the study design is shown in Supplementary Figure S1.
The study was approved by the relevant Institutional Review
Boards, Independent Ethics Committees and Health Authori-
ties, and was conducted in accordance with the Interna-
tional Conference on Harmonisation guideline for Good Clinical
Practice and applicable local regulations, as well as with the
Declaration of Helsinki (World Medical Association, 2013).
Written informed consent was obtained from all patients
before starting the study, and could be withdrawn by the
patient at any time.
Participants
Women aged 36–40 years who were eligible for assisted re-
production techniques were enrolled by PERSIST study inves-
tigators at centres in the European Union and the Russian
Federation. Patients were required to have a body mass index
less than 30 kg/m2, baseline serum FSH level (early follicu-
lar phase) ≤12 IU/l, a normal uterine cavity, both ovaries
present, regular spontaneous ovulatory menstrual cycles (21–
35 days in length) and at least one wash-out cycle (of ≥30 days)
since any prior treatment with clomiphene citrate or gonado-
trophin. Anti-Müllerian hormone (AMH) and antral follicle count
(AFC) were measured but not used as inclusion criteria, as the
study was set up to investigate the role of LH according to a
woman’s chronological and not biological age. Additionally,
patients were excluded if they had experienced a poor re-
sponse (deﬁned as six mature follicles or fewer, four oocytes
collected, or fewer, or both) during two or more previous as-
sisted reproduction technique cycles, had an excessive ovarian
response to any previous assisted reproduction technique cycle
(deﬁned as ≥25 oocytes retrieved) or had received three or
more previous assisted reproduction technique cycles. Women
were also required to have a male partner with semen quality
considered to be acceptable; if this criterion was not met,
women could only enter the study using donor sperm.
Patients with polycystic ovary syndrome, endometriosis re-
quiring treatment, primary ovarian failure, previous experi-
ence of severe ovarian hyperstimulation syndrome (OHSS) or
any contraindication to pregnancy were also excluded from
the study. Other key exclusion criteria were history of three
or more spontaneous abortions (any cause), history or pres-
ence of ovarian enlargement or cysts of unknown cause, clini-
cally signiﬁcant systemic disease or a known allergy or
hypersensitivity to human gonadotrophin preparations.
Interventions
Women who fulﬁlled the eligibility criteria began down-
regulation treatment on cycle days 21–22 using a long
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gonadotrophin-releasing hormone agonist protocol. Once
down-regulation had been conﬁrmed by ultrasound, oestra-
diol levels, or both, and following a negative pregnancy test
result, women were assigned randomly to the 2:1 formula-
tion of rhFSH plus rhLH from stimulation day 1 (group A) or
to rhFSH (GONAL-f; Merck Serono SA, Geneva, Switzerland)
on stimulation days 1–5, followed by rhFSH plus rhLH (2:1)
from stimulation day 6 (group B).
Randomization of patients to the two treatment groupswas
kept balanced in a 1:1 ratio within each centre. A comput-
erized sequence generator was used to randomly allocate
treatment, using centre number as a blocking factor. The ran-
domization sequence was concealed until interventions were
assigned. Centreswere notiﬁed of treatment allocation by fax.
In both treatment groups, daily starting doses of total
gonadotrophin (either rhFSH or rhFSH plus rhLH [2:1]) were
300 IU; dose adjustments in either group were only permit-
ted from stimulation day 6.
Patients received the following interventions according to
each centre’s standard practice. Follicular development was
monitored using ultrasound, oestradiol levels, or both, until
the predeﬁned criteria, of at least one follicle 18 mmorwider
and two follicles 16 mm or wider in diameter, for human cho-
rionic gonadotrophin (HCG) administrationweremet. A single
recombinant HCG injection (r-HCG; 250 µg) was then admin-
istered to induce ﬁnal oocytematuration. Ovum retrieval was
conducted 34–38 h after r-HCGadministration. IVF and embryo
transfer were carried out 2–3 (early cleavage embryos) or 5
days (blastocysts) after oocyte retrieval. No more than three
embryos couldbe transferred in one cycle. Luteal phase support
was provided in the form of daily vaginal progesterone gel.
The start of progesterone for luteal phase support was carried
out according to each centre’s standard practice. The use of
HCG, and oral or injectable progesterone, was not permitted.
Study end-points
The primary end-point was the number of oocytes retrieved
per patient after ovarian stimulation.
Secondary end-points included mean total and mean daily
doses of rhFSH, duration of ovarian stimulation, progester-
one levels before r-HCG administration, implantation rate,
biochemical pregnancy (deﬁned as beta-HCG concentration
>10 IU/l) and clinical pregnancy rate (deﬁned as at least one
gestational sac in the uterus with fetal heart activity con-
ﬁrmed by ultrasound on days 35–42 after HCG).
Safety end-points recorded during the study included the
occurrenceofOHSS, adverse events and serious adverse events.
Statistical analysis
Sample size
Allowing for an estimated non-evaluable/dropout rate of about
10%, a total of about 208 patients were to be recruited and
randomized to ensure a minimum sample size of 188 evaluable
patients (94 per treatment group) for analysis. This sample
size calculation was designed to provide 80% power to
demonstrate the equivalence of the two treatments in number
of oocytes retrieved per patient (primary end-point).
Equivalence was deﬁned as group A having an absolute dif-
ference of no more or no less than three oocytes retrieved
compared with group B. A margin of plus or minus three
oocytes to demonstrate equivalence between two FSH prod-
ucts has been accepted by the European Medicines Agency
as it represents an end-point of clinical relevance (European
Medicines Agency, 2013; Rettenbacher et al., 2015) and is
tighter than that used to register a modiﬁed rhFSH with a
longer half-life (−3, +5) (Devroey et al., 2009).
Populations studied
Efﬁcacy analyses were carried out using a modiﬁed intent-
to-treat population comprising all randomized patients who
received at least one dose of study medication and for whom
data on the number of oocytes retrieved were available
(primary efﬁcacy assessment). The safety population con-
sisted of all randomized patients who had received at least
one dose of study medication.
Primary efﬁcacy analysis of equivalence
A two-way analysis of variance (ANOVA) with treatment and
country as factors was conducted to compare the number of
oocytes retrieved between the two treatment groups. A two-
sided 95% CI was calculated using the standard error of the
difference estimated in the ANOVA model to test the null
hypothesis that the difference in the mean number of oocytes
between the two treatment groups was less than −3 or greater
than 3 compared with the alternative hypothesis that the dif-
ference was between −3 and 3. To demonstrate equiva-
lence of the two treatments, the entire CI was required to
fall within the margins of three oocytes. Least squares means
are reported for the number of oocytes retrieved.
Secondary end-point analyses
All continuous secondary end-points were analysed using an
ANOVA model with treatment and centre as factors. Clinical
pregnancy rate per started cycle and per embryo transferwere
analysed using logistic regression with effects for treatment
and country. No imputation of missing data was conducted.
Results
Patients
This study was conducted between 19 May 2011 and 25 October
2012 at 27 centres in 11 countries (Denmark, Finland, France,
Germany, Greece, Italy, Netherlands, Poland, Russia, Slovakia
and the UK). A total of 202 eligible women were random-
ized (safety population): 103 to group A (rhFSH plus rhLH from
day 1) and 99 to group B (rhFSH on days 1–5, then rhFSH plus
rhLH from day 6) (Figure 1). Baseline demographic and clini-
cal characteristics were similar for patients in the two treat-
ment groups (Table 1).
In total, 101 patients in group A and 98 patients in group
B underwent oocyte retrieval (modiﬁed intention-to-treat
population). Embryo transfer was carried out in 93 and 90
patients in group A and group B, respectively. A similar number
of patients had blastocyst transfers in both groups. In group
A, 24 had blastocyst transfer and one patient had both early
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cleavage and blastocyst transfers, and in group B, 18 had blas-
tocyst transfer and one patient had both early cleavage and
blastocyst transfers.
Almost all patients in the modiﬁed intention-to-treat popu-
lation received vaginal progesterone for luteal phase support
(group A, 96.0%; group B, 94.9%).
Primary end-point
The mean (±standard deviation) number of oocytes re-
trieved per patient was 9.7 (±6.9) in group A and 10.9 (±6.5)
in group B. The estimated difference between the treat-
ment groups (by centre ANOVA) was −1.28 oocytes (95% CI:
−3.15 to 0.59). Equivalence in the number of oocytes retrieved
(difference within ±3 oocytes) in each treatment group was
not shown.
Secondary end-points
Mean daily doses and mean total doses of rhFSH are pre-
sented in Table 2. The mean duration of ovarian stimula-
tion was 10.6 days in both groups (Table 2).
Mean progesterone levels (before r-HCG administration)
were 3.2 nmol/l in group A and 4.0 nmol/l in group B (esti-
mated difference between groups: −0.8 [95% CI: −1.8 to 0.2]
nmol/l).
The numbers of transferred and cryopreserved embryos in
the two treatment groups are shown in Table 3. Rates of
implantation and clinical pregnancy (per started cycle and per
embryo transfer) were 24.7%, 31.6% and 34.4%, respectively,
in group A, and 13.3%, 17.2% and 18.9%, respectively, in group
B (P < 0.05 for comparisons between treatment groups for both
variables; Table 3). The rate of biochemical pregnancy per
started cycle was 39.8% (n = 41) in group A and 23.2% (n = 23)
in group B (P = 0.012).
Figure 1 Patient disposition for those receiving recombinant human follicle-stimulating hormone (rhFSH) plus recombinant human
luteinizing hormone (rhLH) (2:1) from stimulation day 1 (group A), or rhFSH from days 1–5, then rhFSH plus rhLH (2:1) from day 6
(group B). Clinical pregnancy was deﬁned as the presence of at least one gestational sac in the uterus with fetal heart activity con-
ﬁrmed by ultrasound on days 35–42 after HCG. GnRH = gonadotrophin-releasing hormone; mITT = modiﬁed intention-to-treat;
OHSS = ovarian hyperstimulation syndrome.
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One patient in each treatment group discontinued before
oocyte retrieval owing to insufﬁcient ovarian response, and
one patient in group A discontinued owing to an excessive
ovarian response.
Nine patients in group A and six patients in group B expe-
rienced a preclinical spontaneous abortion (deﬁned as a con-
ﬁrmed biochemical pregnancy without evidence of clinical
pregnancy). Patients were followed until conﬁrmation of
clinical pregnancy (days 35–42 after HCG); therefore, data
on clinical spontaneous abortions are not presented.
Safety
Adverse events were reported in 32 out of 103 (31.1%) pa-
tients in group A and in 32 out of 99 (32.3%) patients in
Table 1 Demographic and clinical characteristics of patients receiving recombinant human
FSH (rhFSH) plus recombinant human luteinizing hormone (rhLH) (2:1) from stimulation
day 1 (group A), or rhFSH from days 1–5, then rhFSH plus rhLH (2:1) from day 6 (group B)
(safety population).
Characteristic
Group A (n = 103) Group B (n = 99)
Age (years)
Mean (±SD) 37.4 (±1.1) 37.6 (±1.2)
Median 37.0 38.0
Range 36–40 35a–40
Race (%)
White 89.3 89.9
Other 10.7 10.1
Body mass index (kg/m2)
Mean (±SD) 23.8 (±3.0) 23.4 (±3.3)
Median 23.4 22.4
Range 18.7–31.9b 16.6–29.7
FSH levels at baseline (IU/l)c
Mean (±SD) 7.6 (±2.3) 7.3 (±1.7)
Median 7.2 7.1
Range 3.7–21.9d 3.0–12.1d
Anti-Müllerian hormone levels at
baseline (µg/l)e
Mean (±SD) 1.4 (±1.3) 1.5 (±1.23)
Median 1.1 1.2
Range 0.2–6.7 0.1–7.6
Total antral follicle count at baseline
Mean (±SD) 11.9 (±5.0) 12.4 (±5.1)
Median 12.0 11.5
Range 2–27 3–29
aOne patient was 35 years of age at baseline (minor protocol deviation).
bFour patients had a body mass index of >30 kg/m2 at baseline (minor protocol deviations in
three patients, major protocol violation in one patient).
cGroup A, n = 102; Group B, n = 98.
dFive patients had baseline serum FSH levels of >12 IU/l (minor protocol deviations in two
patients, major protocol violations in three patients).
eGroup A, n = 100; Group B, n = 95.
Table 2 Characteristics of ovarian stimulation in patients receiving recombinant human
FSH (rhFSH) plus recombinant human luteinizing hormone (rhLH) (2:1) from stimulation
day 1 (group A), or rhFSH from days 1–5, then rhFSH plus rhLH (2:1) from day 6 (group B)
(secondary end-points; safety population).
End-point, mean (±SD)
Group A (n = 103) Group B (n = 99)
Total dose of rhFSH(IU) 3321.1 (±850.2) 3292.4 (±851.5)
Daily dose of rhFSH(IU) 310.5 (±40.8) 307.4 (±43.5)
Duration of ovarian stimulation (days) 10.6 (±1.7) 10.6 (±1.6)
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group B. No serious adverse events were reported in group A.
Serious adverse events were reported in two out of 99 (2.0%)
patients in group B; bothwere OHSS events that resolved after
treatment: one mild OHSS (treated with enoxaparin sodium
[40 mg daily] for 2 days and dalteparin sodium [5000 IU daily]
for 7 days) and one severe OHSS (treated on the day of the
serious adverse event with ﬂuconazole [150 mg daily],
clavulanic acid and amoxicillin [625 mg twice daily] and
cabergoline [0.5 mg daily] for 5 days; acetylsalicylic acid
and magnesium hydroxide [15 mg daily] for 10 days; and
hydroxyethyl starch [500 mldaily] fromthedayafter the serious
adverse event started for 5 days; this event resulted in hos-
pitalization and study withdrawal). The patient who experi-
enced the severe OHSS serious adverse event was receiving
triptorelin (0.1 mg) and nadroparin calcium (0.3 ml) daily (both
were stopped 4 days after the serious adverse event started).
In total, OHSS was reported in four out of 103 (3.9%) pa-
tients in group A (two mild and two moderate) and in ﬁve out
of 99 (5.1%) patients in group B (two mild [one serious adverse
event as described earlier], two moderate, one severe [serious
adverse event resulted in study withdrawal as described
earlier]). All cases of OHSS resolved after treatment.
In addition, one serious adverse event (ectopic preg-
nancy) was reported during down-regulation before
randomization.
Discussion
This open-label, randomized study was designed to test equiva-
lence in the number of oocytes retrieved per patient when
rhFSH plus rhLH (2:1) was started immediately (day 1; group
A) or later (day 6; group B) in women aged 36–40 years who
were undergoing ovarian stimulation for assisted reproduc-
tion techniques. The primary end-point of the study was not
met, as the lower 95% CI of the difference in the number of
oocytes retrieved in each treatment group (95% CI −3.15 to
0.59) was not within the prespeciﬁed limits of equivalence
(lower limit: −3). The lack of equivalence of the two treat-
ment strategies was not anticipated.
In the present study, the secondary end-points of clinical
pregnancy rates per started cycle and per embryo transfer
seem to suggest a difference in favour of starting rhFSH plus
rhLH (2:1) on stimulation day 1 compared with starting rhFSH
plus rhLH (2:1) on stimulation day 6 in older women. Despite
the equivalence of oocyte retrieval not being shown, the dif-
ference in clinical pregnancy rates between the two treat-
ment groups may still suggest that rhLH administration from
day 1 could lead to greater improvements in oocyte quality,
uterine receptivity or both, in this patient population than
if administered from day 6. Although these ﬁndings should be
interpreted with caution (as the primary end-point was not
met and the study was not powered to make conclusions about
secondary end-points), further investigation in a larger sample
using clinical pregnancy, live birth or both, as end-points would
be of great interest. The meta-analysis reported by Hill et al.
(2012) found LH supplementation to be associated with higher
rates of implantation and clinical pregnancy in women aged
≥35 years undergoing ovarian stimulation for assisted repro-
duction techniques compared with those receiving rhFSH
alone; however, that study did not explore the optimal day
to initiate LH during ovarian stimulation.
Published evidence suggesting that high levels of LH can
lead to follicular atresia and spontaneous abortion (Howles
et al., 1986; Stanger and Yovich, 1985) has led to the concept
of a ‘therapeutic window’ for LH to stimulate optimal oes-
tradiol production and promote success in assisted reproduc-
tion techniques and ovulation induction (Kumar and Sait, 2011;
Shoham, 2002). The primary end-point of the current study
suggests that both regimens are within the LH therapeutic
Table 3 Treatment outcomes for patients receiving recombinant human follicle-
stimulating hormone (rhFSH) plus recombinant human luteinizing hormone (rhLH ) (2:1)
from stimulation day 1 (group A), or rhFSH from days 1–5, then rhFSH plus rhLH (2:1) from
day 6 (group B) (secondary end-points; modiﬁed intention-to-treat population unless
otherwise speciﬁed).
End-point
Group A (n = 101) Group B (n = 98)
Cancelled ovarian stimulation cycles, % (n)a
Inadequate response 1.0 (1) 1.0 (1)
Excessive response 1.0 (1) 0
Number of oocytes retrieved per patient,
mean (±SD)
9.7 (±6.9) 10.9 (±6.5)
Number of embryos per patient, mean (±SD)
Transferred 1.9 (±0.6) 1.9 (±0.6)
Cryopreserved 4.4 (±4.2) 4.8 (±3.0)
Implantation rate, mean % (±SD)b 24.7 (±36.1) 13.3 (±29.1)
Clinical pregnancy per started cycle, % (n)b 31.6 (32) 17.2 (17)
Clinical pregnancy per embryo transfer, % (n)b,c 34.4 (32) 18.9 (17)
aBefore HCG, calculated as a proportion of the safety population (group A, n = 103; group B,
n = 99).
bP < 0.05 for comparisons between treatment groups.
cCalculated as a proportion of the total number of patients undergoing embryo transfer
(group A, n = 93; group B, n = 90).
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window; secondary end-points, however, suggest there could
be advantages to starting LH earlier.
Safety outcomes were generally comparable between treat-
ment groups, with a similar proportion of patients in each
group reporting adverse events. Three patients experi-
enced a serious adverse event (two with OHSS [both group
B] and one ectopic pregnancy [before randomization]). The
incidence of OHSS was low (reported in four women in group
A and ﬁve women in group B) and led to hospitalization in only
one case (group B).
Although the study had an open-label design, this was not
considered to have affected observed outcomes. Furthermore,
all of the patients’ baseline demographic and clinical char-
acteristics and their pre-HCG stimulation parameters were
similar in the two treatment groups, indicating no clinically
relevant difference between the two groups of randomized
patients.
A recent meta-analysis of 45 studies comparing rhFSH plus
rhLH and rhFSH alone in women undergoing ovarian stimu-
lation for assisted reproduction techniques found signiﬁ-
cantly higher clinical pregnancy rates after LH-supplemented
ovarian stimulation, both in the overall population and more
pronounced in poor responders. In the latter subpopulation,
LH supplementation seemed to increase the number of oocytes
retrieved signiﬁcantly, whereas oocyte numbers did not differ
signiﬁcantly with orwithout LH supplementation in the overall
population. No beneﬁt was found for LH supplementation in
women of advancedmaternal age (>35 years) compared with
youngerwomen;however, unlike thepresent study, this patient
population included poor responders (Lehert et al., 2014).
In summary, studies have shown that LH supplementation
has potential beneﬁts for women aged ≥35 years who are un-
dergoing ovarian stimulation for assisted reproduction tech-
niques, although the use of LH supplementation remains the
subject of debate. In addition, no consensus has currently been
reached on when it is best to initiate LH during ovarian stimu-
lation in these women. The PERSIST study was an open-label
equivalence study to evaluate the ovarian stimulation pro-
ﬁles ofwomenaged 36–40 yearswho had received rhLH supple-
mentation administeredusing twodifferent ovarian stimulation
treatment protocols (initiation of LH supplementation on day
1 or day 6 of stimulation). The difference in the number of
oocytes retrieved in each group (primary end-point analysis)
was not within the predeﬁned limits of equivalence (treat-
ment difference within 3 oocytes), meaning that equiva-
lence of the two treatment strategies was not found. Although
differences in the rates of implantation and pregnancy were
observed between the two treatment groups, no conclusions
can be drawn, as the primary end-point was not met and the
study was not powered to compare these secondary end-
points. It should also be noted that these ﬁndings are based
on data from patients undergoing GnRH agonist cycles. The
potential impact of early versus later rhLHadministrationduring
ovarian stimulation on oocyte quality, uterine receptivity in
older women, or both, is of interest and should be explored
in a large randomized, controlled clinical trial.
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